FTRE
FTRE
US34965K1079
Fortrea Holdings Inc.
Loading chart...

Company Profile

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Latest News

Related stocks

PVLA
PVLA • United States
Palvella Therapeutics, Inc.
138.77 USD
2B USD 1Y +75.5%
GENB
GENB • United States
Generate Biomedicines, Inc.
14.34 USD
1.84B USD
SEPN
SEPN • United States
Septerna, Inc.
38.37 USD
1.79B USD 1Y +64.1%
NTLA
NTLA • United States
Intellia Therapeutics, Inc.
13.07 USD
1.83B USD 1Y -48.5%
NRIX
NRIX • United States
Nurix Therapeutics, Inc.
22.35 USD
2.32B USD 1Y +122.5%
MAZE
MAZE • United States
Maze Therapeutics, Inc.
27.11 USD
1.51B USD 1Y -9.5%
KLRA
KLRA • United States
Kailera Therapeutics, Inc.
11.61 USD
1.51B USD
COAG
COAG • United States
Hemab Therapeutics Holdings, In
31.62 USD
1.48B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
73.6% p.a.
Max Drawdown (3Y)
-89.9%
Sharpe Ratio (3Y)
-0.17
Beta Factor
1.91
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 213%.
Unprofitable business model: The company is currently generating net losses.
High market risk: Beta of 1.91 indicates above-average volatility compared to the broader market.
ende